If you have been watching Elevance Health, you have probably noticed some dramatic moves lately. After a strong bounce of nearly 14% over the last month, the stock recently slipped by 3.5% in just a week. It has not been an easy ride this year, off about 4.5% year to date, and the one-year return is down a steep 28.4%. Despite the rough stretch, Elevance still boasts a solid 26% return if you zoom out to five years. So, what is behind the rollercoaster, and how should investors think about where the stock stands now?

A few things are on investors’ minds. Policy uncertainty, especially around health insurance subsidies and rising ACA plan rates, has made headlines lately. With the government weighing new health insurance subsidies and some insurers asking for double-digit premium hikes on Affordable Care Act plans, risk perceptions are clearly shifting. These stories are fueling both cautious selling and new pockets of optimism about future growth and stability, and you can see this volatility reflected in recent price shifts.

But let’s focus on what matters most for potential buyers: whether Elevance Health is undervalued at these levels. Based on a set of six key valuation checks, Elevance is undervalued on four. That gives it a valuation score of 4, which puts it firmly on the radar for value-oriented investors.

Of course, valuation models come in more flavors than a scoop shop. Let’s dig into the different ways Elevance stacks up on value, and stick around for a look at a smarter approach to understanding what the numbers really mean for your investment decisions.

Why Elevance Health is lagging behind its peers

The Discounted Cash Flow (DCF) model estimates a company's true value by projecting its future cash flows and then discounting those figures back to today's value. For Elevance Health, this involves estimating how much cash the business will generate and what that is worth in present terms.

Currently, Elevance Health is generating annual free cash flow of about $5.15 billion. Analyst forecasts extend approximately five years, expecting free cash flow to climb steadily, reaching $11.31 billion by the end of 2029. Beyond that, future projections are extrapolated out to 2035, when annual free cash flow is estimated to rise to over $15 billion, according to Simply Wall St.

2023 Free Cash Flow: $5.15 billion

2029 Projected Free Cash Flow: $11.31 billion

2035 Projected Free Cash Flow (extrapolated): over $15 billion

The DCF analysis calculates an intrinsic value for Elevance Health of $1,344.87 per share. Based on this analysis, the stock appears 74% undervalued at current prices according to this method.

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Elevance Health.

Our Discounted Cash Flow (DCF) analysis suggests Elevance Health is undervalued by 74.0%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

The Price-to-Earnings (PE) ratio is a widely used metric for valuing profitable companies like Elevance Health because it compares the current stock price to its earnings. This ratio gives investors a quick sense of how much they are paying for each dollar of profit. A higher PE can signal strong growth expectations, while a lower PE might point to skepticism about the company’s prospects or reflect higher risk. The definition of a “normal” or “fair” PE ratio depends on both how fast a company is expected to grow and how reliable its earnings are perceived to be.

Elevance Health currently trades at a PE ratio of 14.7x. For context, the average PE among healthcare peers is 13.3x and the industry average is 20.8x. With these comparisons, Elevance appears slightly more expensive than its peers but less expensive than its broader industry group. However, these benchmarks do not account for unique company factors such as growth, margins, or risk profile.

This is where Simply Wall St’s proprietary “Fair Ratio” comes into play. The Fair Ratio for Elevance Health is estimated at 32.9x. Unlike a basic industry or peer comparison, the Fair Ratio adjusts for Elevance’s earnings growth prospects, profit margins, industry dynamics, market capitalization, and any additional company-specific risks. This makes it a more tailored and insightful benchmark for long-term investors.

Comparing Elevance Health’s current PE of 14.7x with its Fair Ratio of 32.9x suggests that the shares may be undervalued. Investors are paying much less for current earnings than what may be justified, even after accounting for the company-specific factors that are most relevant in practice.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Earlier, we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. A Narrative is a simple yet powerful investment tool that lets you tell the story behind a company by combining your own expectations for Elevance Health’s growth, margins, and risks with those of other investors.

Narratives tie the company’s real-world story to a financial forecast and use that to estimate a fair value, so you can see how your point of view compares with others and the market price. On Simply Wall St’s Community page, Narratives make it easy for anyone to share, compare, and evolve their investment perspectives with just a few clicks.

They are especially useful for deciding when to buy or sell. You can see if the Fair Value based on your assumptions is higher or lower than the current Price, and update your stance whenever fresh news or earnings come out. Narratives are refreshed dynamically with new information.

For example, on Elevance Health, one investor’s Narrative might be very bullish, forecasting a fair value above $500 based on expectations of margin recovery and long-term growth, while a more cautious user might estimate fair value closer to $297 due to ongoing cost and regulatory risks. Narratives give you a structured, data-driven way to express and test your view, helping you invest with confidence in a changing market.

Do you think there's more to the story for Elevance Health? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ELV.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com